Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12109MR)

This product GTTS-WQ12109MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12109MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14456MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ11156MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6738MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ5138MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ12240MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ719MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW